Immutep announces first patient enrolled, dosed in INSIGHT-005 trial

Immutep announces that the first patient has been enrolled and safely dosed in the INSIGHT-005 Phase I trial. The investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate eftilagimod alpha in combination with BAVENCIO in up to 30 patients with metastatic urothelial carcinoma. This chemotherapy-free immuno-oncology combination has already shown promising signals of efficacy and a favorable safety profile in advanced solid tumors, including several IO insensitive indications, in the INSIGHT-004 Phase I trial. Encouragingly, responses were achieved even in cancer patients with low and negative PD-L1 expression, who typically would not be expected to respond to anti-PD-(L)1 therapy.